This trial is studying how well adding olaparib to temozolomide works in treating patients with neuroendocrine cancer.
1 Primary · 3 Secondary · Reporting Duration: From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years
76 Total Participants · 2 Treatment Groups
Primary Treatment: Temozolomide · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: